Bringing together families affected by neuroblastoma from across the globe with those who work to treat, help, and support them.
Neuroblastoma Parent Global Symposium
The Neuroblastoma Parent Global Symposium (NPGS) will return for its fourth year on Friday 3rd November 2023. This is a free, online event to provide support and information to families affected by neuroblastoma, bringing them together with researchers and medical professionals who work to treat and support them.
This year’s event will involve two content tracks - one focussing on the latest developments in neuroblastoma research, and the other on supportive care. Each track will cover these broad themes:
Latest developments in research
Overview of frontline treatment
Treatment for relapse and refractory neuroblastoma
Advances in immunotherapy
Advocacy in research
Post-treatment and late effects
Grief and loss
Stories of hope – living and achieving post-treatment
Sessions will include talks from experts, parents’ perspectives, discussion panels and opportunities for Q&A. The NPGS agenda is curated by parents for parents - stay tuned for an announcement on the full agenda.
If you’d like to explore talks on the following topics presented in previous NPGS events, go to our NPGS YouTube channel.
Solving Kids’ Cancer UK is a parent-led charity, our vision is a future where no child dies of neuroblastoma or suffers due to its treatment. We provide emotional and practical support to families and our research focus is on clinical trials, seeking to explore new ways of treating neuroblastoma, providing hope
Solving Kids' Cancer UK is a registered charity in England and Wales (1135601), and in Scotland (SCO45094). It is a company limited by guarantee in England and Wales (7208646).
Solving Kids’ Cancer is not just our name, it’s our mission. We focus on aggressive childhood cancers with the lowest survival rates—because Every Kid Deserves to Grow Up. Solving Kids' Cancer (SKC) helps accelerate clinical trials of next-generation treatments for brain tumours, neuroblastoma, and sarcomas
by understanding of the global childhood cancer research landscape